Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml

Colloidal Oatmeal


Laboratoires Druide Inc
Human Otc Drug
NDC 71447-030
Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml also known as Colloidal Oatmeal is a human otc drug labeled by 'Laboratoires Druide Inc'. National Drug Code (NDC) number for Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml is 71447-030. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml drug includes Oatmeal - 1.3 g/100g . The currest status of Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml drug is Active.

Drug Information:

Drug NDC: 71447-030
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Nelly Devuyst Bio Medical Bioacne Anti-redness Serum 30 Ml
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Colloidal Oatmeal
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Laboratoires Druide Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:OATMEAL - 1.3 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 14 Oct, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 15 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part347
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:LABORATOIRES DRUIDE INC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2559963
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0829852194619
UPC stands for Universal Product Code.
NUI:N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0006342
M0016962
N0000185016
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:8PI54V663Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Dietary Proteins [CS]
Plant Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Grain Proteins [EXT]
Increased Histamine Release [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71447-030-011 TUBE in 1 BOX (71447-030-01) / 30 g in 1 TUBE (71447-030-00)14 Oct, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose skin protectant

Product Elements:

Nelly devuyst bio medical bioacne anti-redness serum 30 ml colloidal oatmeal coco-caprylate turmeric propanediol polyglyceryl-6 distearate hawthorn leaf with flower glyceryl monostearate nelumbo nucifera root oil jojoba oil, randomized aspalathus linearis leaf sodium stearoyl glutamate yellow wax glycerin cetyl alcohol tocopherol salicylic acid xanthan gum benzyl alcohol potassium sorbate star anise fruit sorbic acid tea tree oil hyaluronate sodium ginger oil glycogen ascorbyl glucoside oatmeal oatmeal

Indications and Usage:

Uses ? temporarily protects and helps relieve minor skin irritations and itching due to eczema rash and dermatitis.

Warnings:

Warnings for external use only

Do Not Use:

Warnings for external use only

When Using:

When using this product keep out of eyes. rinse with water to remove.

Dosage and Administration:

Directions ? apply to affected area as needed.

Stop Use:

Stop use and ask a doctor if rash occurs.

Package Label Principal Display Panel:

Nelly devuyst bio medical bioacne anti-redness serum 30 ml (ndc 71447-030-00) nelly devuys biomedical anti-redness serum 30 ml

Further Questions:

Questions or comments? 1-800-263-8888 outside canada or the united states dial 514-333-8282 or visit www.nellydevuyst.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.